Fairtility™, a Tel Aviv, Israel-based transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced the completion of a $15 million Series A funding, bringing total funding to $18.5 million to date.
The round was led by Boston-based Gurnet Point Capital with support from Nacre Capital and others.
This funding supports the further development of a transparent AI Platform designed to improve IVF outcomes, starting with CHLOE EQ™, Fairtility's Embryo Quality Assessment Assistant.
Fairtility is investing resources from its Series A funding round into advanced clinical research with fertility clinics and marquee academic institutions globally, as well as in regulatory approval processes.
Company: Fairtility Ltd.
Round: Series A
Funding Month: May 2022
Lead Investors: Gurnet Point Capital
Additional Investors: Nacre Capital
Company Website: https://fairtility.com/
Software Category: AI-powered In-Vitro Fertilization (IVF)
About the Company: Fairtility is powering in vitro fertilization (IVF) through transparent AI to improve outcomes. Equipping clinicians and their patients with unparalleled visibility into IVF treatment, CHLOE™ (Cultivating Human Life through Optimal Embryos) is the first and only transparent AI-based decision support tool that provides clinicians with complete visibility into the clinical and laboratory parameters that make up data output to help improve IVF outcomes. Beginning with CHLOE EQ™, a proprietary embryo grading platform, Fairtility is on a path to expand CHLOE™'s application to span the full IVF journey - from infertility cause assessment through transfer optimization.